Non-invasive evaluation of left ventricular hemodynamic force abnormalities in hypertrophic cardiomyopathy: Implications for myosin inhibition
HDF analysis identifies distinct mechanical impairments in HCM regardless of obstruction status. Mavacamten favorably modulates HDF, delaying systolic thrust initiation and normalizing force distribution, offering new mechanistic insights into its therapeutic action in HCM.
Authors
- Manuel Garofalo (ORCID: https://orcid.org/0009-0007-6011-0710)
- Gianni Pedrizzetti (ORCID: https://orcid.org/0000-0003-2886-7653)
- Chiara Zocchi (ORCID: https://orcid.org/0000-0002-6406-4674)
- Giorgia Panichella (ORCID: https://orcid.org/0000-0002-9049-5320)
- Mattia Zampieri (ORCID: https://orcid.org/0000-0002-9339-068X)
- Raffaele Coppini (ORCID: https://orcid.org/0000-0002-4096-3173)
- Maurizio Pieroni (ORCID: https://orcid.org/0000-0002-6830-4292)
- Alessandra Milazzo (ORCID: https://orcid.org/0000-0002-3334-9298)
- Francesco Cappelli (ORCID: https://orcid.org/0000-0002-1622-0732)
- Angela Ilaria Fanizzi
- M Ragagnin
- Annamaria Del Franco
- Iacopo Olivotto
- Raymond H. Chan
Institutions
- University of Trieste (IT)
- Toronto General Hospital (CA)
- Meyer Children's Hospital (IT)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- University of Florence (IT)
Publication Details
- Journal
- International Journal of Cardiology
- Published
- 2026-01-12
- DOI
- https://doi.org/10.1016/j.ijcard.2026.134175
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Sanofi
- Cytokinetics
- Amicus Therapeutics
- Sanofi Genzyme